What's new

Welcome to sihec | Welcome My Forum

Join us now to get access to all our features. Once registered and logged in, you will be able to create topics, post replies to existing threads, give reputation to your fellow members, get your own private messenger, and so, so much more. It's also quick and totally free, so what are you waiting for?

ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility

Hoca

Administrator
Staff member
Joined
Apr 6, 2025
Messages
401
Reaction score
0
Points
0
ProBio, a CDMO and subsidiary of GenScript Biotech, opened its flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell, NJ. The 128,000-sq-ft GMP facility is purpose-built for manufacturing plasmid DNA and viral vectors, including adeno-associated virus (AAV) and lentiviral vector (LVV) platforms.

“This is not just a new facility. It is a beacon of hope for patients waiting for cures,” said Allen Guo, CEO of ProBio. “Opening the Hopewell center is a milestone in ProBio’s global expansion and underscores our mission to support biopharma innovators with high-quality, responsive manufacturing solutions.”

Donavon Decker, the world’s first gene therapy recipient for muscular dystrophy, provided a virtual keynote at ProBio’s grand opening. [ProBio]

Donavon Decker, the world’s first gene therapy recipient for muscular dystrophy, presented a virtual keynote at ProBio’s grand opening. [ProBio]
Bringing over 110 high-skilled jobs to NJ, ProBio’s Hopewell facility continues to expand its capabilities, continued Guo. GMP AAV manufacturing is set to launch by Q3 2025, with GMP LVV services to follow in Q1 2026—enabling support for a broader range of therapeutic candidates from early proof-of-concept through clinical readiness, all within one integrated site, he explained.

The Hopewell site is equipped to support clinical-stage development, process-development, and scaleup for cell and gene therapy programs.

“The opening of ProBio will be a significant enhancement to the cell and gene biologics development and biomanufacturing ecosystem, anchoring New Jersey as a leader in the field. The potential to support production for global clinical trial registrations and close proximity to leading precision medical centers will enable faster access of breakthrough medicines to patients,” noted John Coelho, of the New Jersey Economic Development Authority (NJEDA).



The post ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility appeared first on GEN - Genetic Engineering and Biotechnology News.
 
Top Bottom